Effect of various doses of acetylsalicylic acid in combination with dipyridamole on the balance between prostacyclin and thromboxane in human serum

British Journal of Pharmacology
L Viinikka, O Ylikorkala

Abstract

1 Thirty-six healthy human subjects were randomly divided into six groups which were treated with a single dose of 75 mg (1.3 mg/kg) of dipyridamole alone, or 75 mg of dipyridamole in combination with 30 mg (0.5 mg/kg), 50 mg (0.8 mg/kg), 160 mg (2.6 mg/kg) and 330 mg (5.7 mg/kg) of acetylsalicylic acid (ASA), or with placebo. 2 The concentrations of prostacyclin (PGI2) and thromboxane A2 (TxA2) metabolites, 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) and TxB2 respectively, were measured in serum with specific radioimmunoassays before and 1 and 3 h afer the ingestion of the test dose. 3 The basal concentrations of 6-keto-PGF1 alpha and TxB2 correlated significantly (r = 0.588, P less than 0.001). 4 Dipyridamole alone did not change PGI2 or TxA2 production. 5 Dipyridamole-ASA combinations with ASA doses between 0.5 and 0.8 mg/kg inhibited TxB2 production by 48 to 74% and with the ASA doses between 2.6 and 5.7 mg/kg by about 90%. None of these combinations changed PGI2 production. 6 The ratio of 6-keto-PGF1 alpha to TxB2 increased 3.5 to 6 times with ASA doses of 0.5 to 0.8 mg/kg and 21 to 29 times with doses between 2.6 to 5.7 mg/kg. 7 These results suggest that the anti-thrombotic effect of dipyridamole in vivo is not med...Continue Reading

References

Dec 1, 1976·Prostaglandins·N WhittakerF F Sun
Dec 22, 1979·Lancet·P C Elwood, P M Sweetnam
May 17, 1979·The New England Journal of Medicine·S Moncada, J R Vane
Feb 1, 1978·The Journal of Clinical Investigation·J W BurchP W Majerus
Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·G J RothP W Majerus
Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·M HambergB Samuelsson
Sep 1, 1975·The Journal of Clinical Investigation·G J Roth, P W Majerus
Mar 9, 1974·British Medical Journal
Feb 26, 1972·British Medical Journal·M GirominiM Jeannet
Jun 23, 1971·Nature: New Biology·J B Smith, A L Willis
Dec 10, 1970·The New England Journal of Medicine·L A Harker, S J Slichter
Sep 12, 1968·The New England Journal of Medicine·J M SullivanR Gorlin
Nov 16, 1968·British Medical Journal·K E ArforsN A Matheson
Jan 1, 1980·British Journal of Pharmacology·K E BlassK Pönicke
Oct 1, 1980·Prostaglandins·L Viinikka, O Ylikorkala

❮ Previous
Next ❯

Citations

Jan 1, 1983·European Journal of Clinical Pharmacology·E NuottoU Lamminsivu
Apr 1, 1982·Prostaglandins·I A BlairC T Dollery
May 1, 1983·Prostaglandins, Leukotrienes, and Medicine·P UotilaT Puustinen
Sep 1, 1985·Prostaglandins, Leukotrienes, and Medicine·B Rosenkranz, J C Frölich
Aug 1, 1986·American Journal of Obstetrics and Gynecology·O YlikorkalaL Viinikka
Sep 1, 1987·The British Veterinary Journal·P LeesA D Sedgwick
Jan 1, 1990·Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum·L Viinikka
Nov 1, 1984·Drug Intelligence & Clinical Pharmacy·M P RiveyJ W Taylor

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.